These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32102582)

  • 1. CD30 expression and survival in posttransplant lymphoproliferative disorders.
    Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
    Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes.
    Berglund D; Kinch A; Edman E; Backlin C; Enblad G; Larsson E; Molin D; Pauksens K; Sundström C; Baecklund E
    Transplantation; 2015 May; 99(5):1036-42. PubMed ID: 25211518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders.
    Vase MØ; Maksten EF; Bendix K; Hamilton-Dutoit S; Andersen C; Møller MB; Sørensen SS; Jespersen B; Kampmann J; Søndergård E; Nielsen PS; D'amore F
    Leuk Lymphoma; 2015 Jun; 56(6):1677-85. PubMed ID: 25248878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.
    Hartley C; Vaughan JW; Jarzembowski J; Kroft SH; Hosking P; Harrington AM; Olteanu H
    Am J Clin Pathol; 2017 Nov; 148(6):485-493. PubMed ID: 29126177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S; Webber S; Ahuja S; Jaffe R
    Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.
    Proust A; Rincé P; Creidy R; Lazure T; Joab I; Garçon L; Fabre M; Guettier C; Raphael M
    Am J Pathol; 2011 Oct; 179(4):1630-7. PubMed ID: 21871426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status.
    Poirel HA; Bernheim A; Schneider A; Meddeb M; Choquet S; Leblond V; Charlotte F; Davi F; Canioni D; Macintyre E; Mamzer-Bruneel MF; Hirsch I; Hermine O; Martin A; Cornillet-Lefebvre P; Patey M; Toupance O; Kémény JL; Deteix P; Raphaël M
    Transplantation; 2005 Jul; 80(2):176-84. PubMed ID: 16041261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.
    Courville EL; Yohe S; Chou D; Nardi V; Lazaryan A; Thakral B; Nelson AC; Ferry JA; Sohani AR
    Mod Pathol; 2016 Oct; 29(10):1200-11. PubMed ID: 27443517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?
    Nelson BP; Nalesnik MA; Bahler DW; Locker J; Fung JJ; Swerdlow SH
    Am J Surg Pathol; 2000 Mar; 24(3):375-85. PubMed ID: 10716151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases.
    Herreman A; Dierickx D; Morscio J; Camps J; Bittoun E; Verhoef G; De Wolf-Peeters C; Sagaert X; Tousseyn T
    Leuk Lymphoma; 2013 Oct; 54(10):2190-9. PubMed ID: 23402267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
    Salmerón-Villalobos J; Castrejón-de-Anta N; Guerra-García P; Ramis-Zaldivar JE; López-Guerra M; Mato S; Colomer D; Diaz-Crespo F; Menarguez J; Garrido-Pontnou M; Andrés M; García-Fernández E; Llavador M; Frigola G; García N; González-Farré B; Martín-Guerrero I; Garrido-Colino C; Astigarraga I; Fernández A; Verdú-Amorós J; González-Muñíz S; González B; Celis V; Campo E; Balagué O; Salaverria I
    Blood; 2023 Aug; 142(5):434-445. PubMed ID: 37053555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
    Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
    J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
    Krishnamurthy S; Hassan A; Frater JL; Paessler ME; Kreisel FH
    Int J Surg Pathol; 2010 Aug; 18(4):278-85. PubMed ID: 19578050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.
    Sundin A; Grzywacz BJ; Yohe S; Linden MA; Courville EL
    Hum Pathol; 2017 Mar; 61():140-147. PubMed ID: 27993575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.